Development of Multistaged Nanoparticles as Cancer Vaccines

Flavia Fontana; Mohammad-Ali Shahbazi; Dongfei Liu; Hongbo Zhang; Ermei Mäkilä; Jarno Salonen; Jouni Tapio Hirvonen; Helder Almeida Santos

Abstract

Nanoparticles present suitable characteristics for use as vaccine adjuvants due to their size, the natural target in the lymph nodes, the possibility to co-deliver antigens and adjuvants, as well as the intrinsic adjuvant effect shown by some nanomaterials.1-3 We propose a multistaged cancer nanovaccine made of an adjuvant nanoparticle and an innovative source of neoantigens, vesicles derived from the membrane of cancer cells, coating the nanoparticles. The adjuvant nanoparticles were prepared by nanoprecipitation in a glass capillary microfluidic device from porous silicon nanoparticles and acetalated dextran. The nanovectors were highly cytocompatible for peripheral blood monocytes (PBMC) isolated from healthy donors and immortalized cell lines. Moreover, they induced the expression of co-stimulatory signals (CD80 and 86), the secretion of pro-inflammatory cytokines (IFN-γ), and inhibited, when incubated with the activated PBMCs, the proliferation of cancer cells of the same cell line used as source of membranes. Overall, the developed system showed excellent properties as adjuvant in vitro, with promising future applications in personalized treatments for cancer immunotherapy.

References

1. D. J. Irvine, M. C. Hanson, K. Rakhra and T. Tokatlian, Chem rev, 2015, 115, 11109-11146.
2. F. Fontana, D. Liu, J. Hirvonen and H. A. Santos, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2016, DOI: 10.1002/wnan.1421.
3. K. T. Gause, A. K. Wheatley, J. Cui, Y. Yan, S. J. Kent and F. Caruso, ACS Nano, 2017, 11, 54-68.

Original language	English
Publication status	Published - 2017
Externally published	Yes
Event	International School of Nanomedicine: New Trends in Nanomedicine - Ettore Majorana Foundation And Center for Scientific Culture, Erice, Italy Duration: 8-Apr-2017 → 13-Apr-2017

Course

Course	International School of Nanomedicine
Country/Territory	Italy
City	Erice
Period	08/04/2017 → 13/04/2017

Keywords

317 Pharmacy
Nanotechnology
Nanovaccine
Immunotherapy
Cancer

Handle.net

Persistent link

Cite this

@conference{1724c566271c40728aa4783624abb5f5,

title = "Development of Multistaged Nanoparticles as Cancer Vaccines",

abstract = "Nanoparticles present suitable characteristics for use as vaccine adjuvants due to their size, the natural target in the lymph nodes, the possibility to co-deliver antigens and adjuvants, as well as the intrinsic adjuvant effect shown by some nanomaterials.1-3 We propose a multistaged cancer nanovaccine made of an adjuvant nanoparticle and an innovative source of neoantigens, vesicles derived from the membrane of cancer cells, coating the nanoparticles. The adjuvant nanoparticles were prepared by nanoprecipitation in a glass capillary microfluidic device from porous silicon nanoparticles and acetalated dextran. The nanovectors were highly cytocompatible for peripheral blood monocytes (PBMC) isolated from healthy donors and immortalized cell lines. Moreover, they induced the expression of co-stimulatory signals (CD80 and 86), the secretion of pro-inflammatory cytokines (IFN-γ), and inhibited, when incubated with the activated PBMCs, the proliferation of cancer cells of the same cell line used as source of membranes. Overall, the developed system showed excellent properties as adjuvant in vitro, with promising future applications in personalized treatments for cancer immunotherapy. References 1. D. J. Irvine, M. C. Hanson, K. Rakhra and T. Tokatlian, Chem rev, 2015, 115, 11109-11146. 2. F. Fontana, D. Liu, J. Hirvonen and H. A. Santos, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2016, DOI: 10.1002/wnan.1421. 3. K. T. Gause, A. K. Wheatley, J. Cui, Y. Yan, S. J. Kent and F. Caruso, ACS Nano, 2017, 11, 54-68.",

keywords = "317 Pharmacy, Nanotechnology, Nanovaccine, Immunotherapy, Cancer",

author = "Flavia Fontana and Mohammad-Ali Shahbazi and Dongfei Liu and Hongbo Zhang and Ermei M{\"a}kil{\"a} and Jarno Salonen and Hirvonen, \{Jouni Tapio\} and \{Almeida Santos\}, Helder",

year = "2017",

language = "English",

note = "International School of Nanomedicine : New Trends in Nanomedicine ; Conference date: 08-04-2017 Through 13-04-2017",

}

TY - CONF

T1 - Development of Multistaged Nanoparticles as Cancer Vaccines

AU - Fontana, Flavia

AU - Shahbazi, Mohammad-Ali

AU - Liu, Dongfei

AU - Zhang, Hongbo

AU - Mäkilä, Ermei

AU - Salonen, Jarno

AU - Hirvonen, Jouni Tapio

AU - Almeida Santos, Helder

PY - 2017

Y1 - 2017

N2 - Nanoparticles present suitable characteristics for use as vaccine adjuvants due to their size, the natural target in the lymph nodes, the possibility to co-deliver antigens and adjuvants, as well as the intrinsic adjuvant effect shown by some nanomaterials.1-3 We propose a multistaged cancer nanovaccine made of an adjuvant nanoparticle and an innovative source of neoantigens, vesicles derived from the membrane of cancer cells, coating the nanoparticles. The adjuvant nanoparticles were prepared by nanoprecipitation in a glass capillary microfluidic device from porous silicon nanoparticles and acetalated dextran. The nanovectors were highly cytocompatible for peripheral blood monocytes (PBMC) isolated from healthy donors and immortalized cell lines. Moreover, they induced the expression of co-stimulatory signals (CD80 and 86), the secretion of pro-inflammatory cytokines (IFN-γ), and inhibited, when incubated with the activated PBMCs, the proliferation of cancer cells of the same cell line used as source of membranes. Overall, the developed system showed excellent properties as adjuvant in vitro, with promising future applications in personalized treatments for cancer immunotherapy. References 1. D. J. Irvine, M. C. Hanson, K. Rakhra and T. Tokatlian, Chem rev, 2015, 115, 11109-11146. 2. F. Fontana, D. Liu, J. Hirvonen and H. A. Santos, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2016, DOI: 10.1002/wnan.1421. 3. K. T. Gause, A. K. Wheatley, J. Cui, Y. Yan, S. J. Kent and F. Caruso, ACS Nano, 2017, 11, 54-68.

AB - Nanoparticles present suitable characteristics for use as vaccine adjuvants due to their size, the natural target in the lymph nodes, the possibility to co-deliver antigens and adjuvants, as well as the intrinsic adjuvant effect shown by some nanomaterials.1-3 We propose a multistaged cancer nanovaccine made of an adjuvant nanoparticle and an innovative source of neoantigens, vesicles derived from the membrane of cancer cells, coating the nanoparticles. The adjuvant nanoparticles were prepared by nanoprecipitation in a glass capillary microfluidic device from porous silicon nanoparticles and acetalated dextran. The nanovectors were highly cytocompatible for peripheral blood monocytes (PBMC) isolated from healthy donors and immortalized cell lines. Moreover, they induced the expression of co-stimulatory signals (CD80 and 86), the secretion of pro-inflammatory cytokines (IFN-γ), and inhibited, when incubated with the activated PBMCs, the proliferation of cancer cells of the same cell line used as source of membranes. Overall, the developed system showed excellent properties as adjuvant in vitro, with promising future applications in personalized treatments for cancer immunotherapy. References 1. D. J. Irvine, M. C. Hanson, K. Rakhra and T. Tokatlian, Chem rev, 2015, 115, 11109-11146. 2. F. Fontana, D. Liu, J. Hirvonen and H. A. Santos, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2016, DOI: 10.1002/wnan.1421. 3. K. T. Gause, A. K. Wheatley, J. Cui, Y. Yan, S. J. Kent and F. Caruso, ACS Nano, 2017, 11, 54-68.

KW - 317 Pharmacy

KW - Nanotechnology

KW - Nanovaccine

KW - Immunotherapy

KW - Cancer

M3 - Abstract

T2 - International School of Nanomedicine

Y2 - 8 April 2017 through 13 April 2017